Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00315861 · ClinicalTrials.gov registry record · Phase 1
Topotecan in Combination With Pemetrexed in Patients With Advanced Malignancies
A Phase 1 study of Lung Cancer and Ovarian Cancer, sponsored by SCRI Development Innovations.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT00315861: Completed Phase 1 study of Lung Cancer and Ovarian Cancer, sponsored by SCRI Development Innovations.
NCT00315861 is a Phase 1 study of Lung Cancer and Ovarian Cancer that has completed, run by SCRI Development Innovations. The registered enrollment target is 15 participants, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00315861, a Phase 1 study of Lung Cancer and Ovarian Cancer, has completed, sponsored by SCRI Development Innovations.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
Currently, no data exists regarding the safety and tolerability of a combination regimen utilizing weekly topotecan in combination with pemetrexed. Although both drugs are associated with myelosuppression, it is hoped that the utilization of the weekly topotecan dosing schedule will allow the drugs to be easily combined. This phase I trial will evaluate the safety and tolerability of weekly topotecan in combination with pemetrexed in patients with advanced solid tumors.
Conditions Studied
Interventions
- DRUG pemetrexed
- DRUG topotecan
Study Locations (1)
Tennessee
- Tennessee Oncology, PLLC - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2006-03 |
| Est. Completion | 2009-01 |
| Phase | Phase 1 |
What the finished NCT00315861 record still lists
NCT00315861 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (98% lower).
The record links to 4 conditions, with Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which pemetrexed is the first listed.
NCT00315861 reports a single indexed study location in Tennessee.
Frequently Asked Questions
What is clinical trial NCT00315861 about?
NCT00315861 is a clinical study titled "Topotecan in Combination With Pemetrexed in Patients With Advanced Malignancies". Currently, no data exists regarding the safety and tolerability of a combination regimen utilizing weekly topotecan in combination with pemetrexed. Although both drugs are associated with myelosuppression, it is hoped that the utilization of the weekly topotecan dosing schedule will allow the drugs ...
What is the current status of trial NCT00315861?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2006-03. Estimated completion is 2009-01.
What conditions does trial NCT00315861 study?
This clinical trial studies the following conditions: Lung Cancer, Ovarian Cancer, Endometrial Cancer, Cervical Cancer.
What interventions are being tested in trial NCT00315861?
The interventions under investigation include: pemetrexed (DRUG), topotecan (DRUG).
Who is sponsoring clinical trial NCT00315861?
This trial is sponsored by SCRI Development Innovations, which has 146 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00315861 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00315861's enrollment target sits among peer trials
15 378th of 409 higher than 31 of 409 other Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RECRUITING · Phase 1
-
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
RECRUITING · Phase 1
-
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia